Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands... Show more
Emerson Electric (EMR) enters August 2026 with renewed upward momentum after a volatile stretch earlier in the summer. The stock touched an intraday low of $134.20 on July 8 before staging a steady recovery, punctuated by a 3.9% surge on July 23 following the JPMorgan upgrade. Broader industrial sector sentiment has improved as rig count forecasts and refinery capital expenditure projections tick higher, and Emerson's heavy exposure to long-cycle automation projects provides a degree of insulation against shorter-term macro uncertainty. With institutional ownership sitting at approximately 74.3% of outstanding shares and several major holders—including Norges Bank, Vanguard, and State Street—adding to positions in recent quarters, institutional conviction in the automation thesis remains evident.
Emerson Electric Co., headquartered in St. Louis, Missouri, is a global technology and engineering leader specializing in automation solutions for industrial, commercial, and residential markets. The company operates through two principal platforms: Automation Solutions, which delivers process automation systems, measurement and analytical instrumentation, valves and actuators, control software, and aftermarket services; and Commercial & Residential Solutions, which provides climate control products, tools, and storage solutions. Emerson has undergone a significant portfolio transformation, most notably completing the sale of a majority stake in its Climate Technologies business—now operating independently as Copeland under Blackstone's control—in a deal valued at $14 billion that generated approximately $9.7 billion in pre-tax cash proceeds. This repositioning allows Emerson to concentrate on high-growth automation end markets including power generation, LNG, life sciences, semiconductors, and aerospace & defense. The March 2025 acquisition of the remaining AspenTech shares made the industrial software leader a wholly owned subsidiary, further cementing Emerson's software-defined automation strategy.
The most consequential catalyst over the past 30 days was JPMorgan's July 17 upgrade to Overweight with a $157 price target. The firm highlighted Emerson's $8.2 billion backlog—up 9% year-over-year—and the phasing of large, long-cycle projects as key drivers for the second half of fiscal 2026. JPMorgan also pointed to upside potential from Middle East rehabilitation work not yet reflected in company guidance, alongside improving flows through the Persian Gulf and an upward revision in rig count and refiner capex forecasts. Earlier in the quarter, Bernstein initiated coverage with an Outperform rating and a $175 target (later adjusted to $169), while RBC raised its target to $169. On the product front, Emerson launched two new refinery optimization tools—Crude Schedule Optimization and Multi-Blend Optimization—under the Aspen Unified Scheduling platform, and announced a partnership with SiMa.ai to embed advanced AI capabilities into industrial PCs for real-time, cloud-independent data analysis. The company also enhanced its AspenTech Inmation OT Data Fabric to support edge-to-cloud data management. Emerson's Q2 2026 results, reported May 5, showed adjusted EPS of $1.54 slightly ahead of consensus, with growth verticals surging 22% and software annual contract value reaching $1.64 billion. Full-year guidance was updated to $6.45–$6.55 adjusted EPS with approximately $2.2 billion planned for shareholder returns through dividends and buybacks.
For traders seeking data-driven approaches to navigating stocks like Emerson Electric, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across diverse strategies, timeframes, and risk profiles. The Trending AI Robots section filters this extensive universe to spotlight only the most relevant and highest-performing bots, making it easier for users to identify strategies aligned with current market conditions. Whether focused on short-term swing trades, longer-term trend following, or pattern recognition, each bot is tracked with transparent performance metrics. Exploring the Trending AI Robots page can help investors discover automated strategies that complement their own research on stocks like EMR.
Emerson's immediate focus is the August 4 Q3 earnings report, where investors will scrutinize execution across the Intelligent Devices and Software & Systems segments. Consensus forecasts point to EPS of $1.68 on approximately $4.79 billion in revenue, with particular attention on software ACV growth, backlog conversion rates, and any adjustments to full-year guidance in light of the ongoing Middle East conflict—which management previously modeled as a roughly one-percentage-point headwind. Beyond earnings, key themes for the remainder of 2026 include the trajectory of the $11.2 billion project funnel, progress in AI-enabled industrial automation deployments, and the pace of capital returns under Emerson's $2.2 billion shareholder return plan. Macroeconomic factors—including interest rate policy, industrial production trends in China and Europe, and energy sector capital spending—will continue to influence demand across Emerson's end markets. Analysts also expect the company's portfolio reshaping initiatives and software-focused acquisitions to begin contributing more meaningfully to margin expansion as fiscal 2027 approaches.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EMR saw its Momentum Indicator move below the 0 level on August 18, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In of the 93 cases, the stock moved further down in the following days. The odds of a decline are at .
The 10-day RSI Indicator for EMR moved out of overbought territory on August 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 61 cases where EMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EMR broke above its upper Bollinger Band on July 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Moving Average Convergence Divergence (MACD) for EMR just turned positive on July 22, 2026. Looking at past instances where EMR's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
EMR moved above its 50-day moving average on July 23, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EMR crossed bullishly above the 50-day moving average on July 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in of 333 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 269 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.314) is normal, around the industry mean (6.130). P/E Ratio (34.486) is within average values for comparable stocks, (75.015). Projected Growth (PEG Ratio) (1.816) is also within normal values, averaging (2.162). Dividend Yield (0.014) settles around the average of (0.018) among similar stocks. P/S Ratio (4.764) is also within normal values, averaging (204.626).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of process controls systems, valves and analytical instruments
Industry IndustrialMachinery